For the quarter ending 2026-03-31, RCUS had -$21M decrease in cash & cash equivalents over the period. -$138M in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 17 | 33 | 214 | - |
| Late-stage development programs | 60 | 67 | 207 | - |
| Early-stage development and preclinical programs | 18 | 28 | 113 | - |
| Compensation and personnel costs | 70 | 58 | 187 | - |
| Depreciation and amortization | 2 | 3 | 7 | - |
| Impairment of long-lived assets | - | 0 | 0 | - |
| Interest income, net | -6 | -8 | -25 | - |
| Income tax expense | - | 0 | 0 | - |
| Other segment items | 20 | 19 | 71 | - |
| Partnership reimbursements | -19 | -28 | -99 | - |
| Net loss | -128 | -106 | -135 | -112 |
| Stock-based compensation expense | 19 | 15 | 14 | 31 |
| Depreciation and amortization | 2 | 3 | 2 | 5 |
| Noncash lease expense | 2 | 2 | 2 | 3 |
| Impairment on right-of use assets | - | 0 | 0 | 0 |
| Amortization of discounts on marketable securities | 3 | 3 | 3 | 7 |
| Other items, net | 1 | -1 | 2 | 0 |
| Receivable from collaboration partners ( and 2 from a related party) | -8 | 0 | -4 | -5 |
| Other assets | 3 | 0 | -6 | 1 |
| Accounts payable ((13) and to a related party) | -3 | 0 | 13 | 11 |
| Deferred revenue ((15) and (28) to a related party) | -17 | -26 | -26 | -188 |
| Other liabilities | -16 | -4 | 24 | -12 |
| Net cash used in operating activities | -138 | -120 | -97 | -265 |
| Purchases of marketable securities | 150 | 397 | 165 | 514 |
| Proceeds from maturities of marketable securities | 257 | 215 | 243 | 615 |
| Proceeds from sales of marketable securities | 7 | 1 | 1 | 69 |
| Purchases of property and equipment | 0 | 1 | 0 | 1 |
| Proceeds from debt issuances, net | - | 0 | 0 | 49 |
| Net cash provided by investing activities | 114 | -182 | 79 | 169 |
| Proceeds from issuance of common stock ( and 14 from a related party) | 0 | 279 | 8 | 142 |
| Proceeds from issuance of common stock pursuant to equity award plans | 3 | 7 | 0 | 3 |
| Payments of employee taxes related to net settlement of equity awards | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 3 | 286 | 8 | 194 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -21 | -16 | -10 | 98 |
| Cash, cash equivalents and restricted cash at beginning of period | 225 | 241 | 153 | - |
| Cash, cash equivalents and restricted cash at end of period | 204 | 225 | 241 | - |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)